Abbott’s Q2 Medical Device And Diagnostic Sales Surpass 2019 Levels
Executive Summary
Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.
You may also be interested in...
Minute Insight: Big Medtechs Usually Do Well During High Inflation, But Not in 2021
A new analysis from Wells Fargo found that the big medtech stocks typically perform at least as well as the overall market when inflationary expectations are high, but 2021 defied that trend.
Abbott Becomes Third US TAVR Competitor With Portico Approval
Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.
FDA Approves Abbott’s Amplatzer Amulet LAA Occluder To Compete With Boston Scientific’s Watchman
Amplatzer Amulet is a percutaneous transcatheter device designed to prevent thrombus embolization from the left-atrial appendage in people with nonvalvular atrial fibrillation.